Omkar Pharmachem Ltd
Incorporated in 1995, Omkar Pharmachem Ltd manufactures chemicals used in pharmaceuticals.
- Market Cap ₹ 30.0 Cr.
- Current Price ₹ 29.7
- High / Low ₹ 30.1 / 25.5
- Stock P/E 214
- Book Value ₹ 9.43
- Dividend Yield 0.00 %
- ROCE 3.04 %
- ROE 2.14 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.15 times its book value
- Promoter holding is low: 0.03%
- Company has a low return on equity of 2.15% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.27 | 0.54 | 0.54 | 0.54 | 0.54 | 0.56 | |
| 0.07 | 0.06 | 0.12 | 0.22 | 0.24 | 0.38 | 0.26 | 0.24 | 0.27 | 0.22 | 0.25 | 0.24 | 0.29 | |
| Operating Profit | 0.00 | -0.06 | -0.12 | -0.22 | -0.24 | -0.38 | -0.21 | 0.03 | 0.27 | 0.32 | 0.29 | 0.30 | 0.27 |
| OPM % | 0.00% | -420.00% | 11.11% | 50.00% | 59.26% | 53.70% | 55.56% | 48.21% | |||||
| 0.00 | 0.00 | 0.00 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.05 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.02 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Profit before tax | 0.00 | -0.06 | -0.12 | 0.27 | -0.25 | -0.42 | -0.26 | -0.03 | 0.21 | 0.27 | 0.26 | 0.27 | 0.25 |
| Tax % | 0.00% | 0.00% | 18.52% | 0.00% | 0.00% | 0.00% | -866.67% | 14.29% | 25.93% | 23.08% | 25.93% | ||
| 0.00 | -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.14 | |
| EPS in Rs | 0.00 | -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.14 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 61% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 4% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 8% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 |
| Reserves | -0.75 | -0.81 | -0.93 | -0.71 | -0.96 | -1.38 | -1.64 | -1.42 | -1.24 | -1.04 | -0.85 | -0.65 | -0.57 |
| 0.01 | 0.01 | 0.00 | 0.00 | 0.24 | 0.58 | 0.87 | 0.90 | 0.93 | 0.62 | 0.30 | 0.12 | 0.00 | |
| 0.11 | 0.13 | 0.57 | 0.06 | 0.04 | 0.05 | 0.06 | 0.08 | 0.06 | 0.07 | 0.07 | 0.05 | 0.04 | |
| Total Liabilities | 9.45 | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 9.55 |
| 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 |
| 0.14 | 0.10 | 0.41 | 0.13 | 0.09 | 0.03 | 0.07 | 0.34 | 0.52 | 0.43 | 0.29 | 0.29 | 0.24 | |
| Total Assets | 9.45 | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 9.55 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | -0.05 | 0.34 | -0.77 | -0.25 | -0.30 | -0.21 | 0.02 | 0.20 | 0.28 | 0.30 | 0.24 | |
| 0.00 | 0.00 | 0.00 | 0.49 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | |
| 0.00 | 0.00 | -0.01 | 0.01 | 0.23 | 0.30 | 0.24 | -0.02 | -0.03 | -0.35 | -0.35 | -0.20 | |
| Net Cash Flow | 0.01 | -0.05 | 0.33 | -0.28 | -0.03 | 0.00 | 0.02 | 0.00 | 0.17 | -0.08 | -0.06 | 0.04 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | |||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 365.00 | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | |||||
| Working Capital Days | -52.14 | -6,570.00 | -1,270.74 | -608.33 | -378.52 | -162.22 | -6.76 | |||||
| ROCE % | 0.00% | -0.64% | -1.30% | -2.27% | -2.56% | -4.08% | -2.26% | 0.32% | 2.79% | 3.29% | 3.02% | 3.04% |
Documents
Announcements
-
Re-Lodgment Of Transfer Requests For The Months Of October And November 2025
12 Dec - No re-lodgement requests received/processed for Oct–Nov 2025 under SEBI special window.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Dear Sir, Please find newspaper Advertisement of Unaudited Financial Statement for the Quarter & half yearly ended on 30.09.2025.
- Results- Unaudited Financial Results For September, 2025 14 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14Th November, 2025
14 Nov - Board approved unaudited results for quarter/half-year ended 30 Sep 2025.
-
Board Meeting Intimation for Board Meeting Intimation For Inter-Alia, To Consider, Approve And Take On Record The Unaudited Standalone Financial Results Of The Company For The Quarter And Half Yearly Ended September 30, 2025
6 Nov - Board meeting on Nov 14, 2025 to approve Q2/H1 unaudited results; trading window closed until Nov 16, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Profile:[1][2]
a) Sodium bi-sulphite
b) Sodium meta bi-sulphite
c) Sodium sulphite
d) Sulphur
e) Specialty chemicals
f) Ciba specialty chemicals
g) Organic chemicals